Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases

Skin disease may be related with immunological disorders, external aggressions, or genetic conditions. Injuries cutaneous diseases such as wounds, burns, psoriasis, and scleroderma among others are common pathologies in dermatology, some cases, conventional treatments ineffective. In recent years, advanced therapies using human mesenchymal stem cells (hMSCs) from different sources has emerged a promising strategy for the treatment of many pathologies. Due to their properties; regenerative, immunomodulatory differentiation capacities, they could applied diseases. this review, total thirteen types hMSCs used therapy have been analyzed, considering last 5 years (2015–2020). The most investigated were those isolated umbilical cord blood (hUCB-MSCs), adipose tissue (hAT-MSCs) bone marrow (hBM-MSCs). studied wounds ulcers, burns psoriasis. At preclinical level, vivo studies mice rats main animal models used, wide range used. Clinical analyzed revealed that cell by intravenous administration was preferred except case where engineering also reported. Although clinical trials reviewed results not posted yet, safety high only local slight adverse events (mild nausea abdominal pain) terms effectiveness, it difficult compare due doses administered variables measured, but general, percentage wound’s size reduction higher than 80% Psoriasis Area Severity Index Scoring Atopic Dermatitis significantly reduced, scleroderma, parameters Modified Rodnan skin score (MRSC) European Scleroderma Study Group activity index reported an improvement hypertrophic scars, Vancouver Scar Scale (VSS) decreased after applying these therapies. On balance, is strategy, however, experimental designs endpoints stablished each study, makes necessary more research find best way treat patient disease.